Abstract | BACKGROUND: METHODS: This post-hoc analysis evaluated the proportions of patients achieving individual diabetes-related QMs using data from the randomized, double-blind, Phase 3 CANTATA-SU trial. Change in A1C from baseline, and proportions of the study population achieving QMs: A1C <7.0 %, <8.0 %, and >9.0 % were assessed. Secondary endpoints included change in BP from baseline, and the proportions of the study population achieving QMs related to BP and body weight. RESULTS: CONCLUSIONS: Using the recently adjusted and currently accepted diabetes-related QMs, this analysis observed superior glycemic control with canagliflozin compared with maximally tolerated glimepiride in patients with T2DM who were previously poorly controlled on metformin monotherapy. Compared with maximally tolerated glimepiride, canagliflozin resulted in better achievement of diabetes-related QMs related to weight loss and BP, and was associated with lower incidences of hypoglycemic events. TRIAL REGISTRATION: CLINICAL TRIAL REGISTRATION NUMBER: NCT00968812 , registered August 28, 2009.
|
Authors | Charmi A Patel, Robert A Bailey, Ujjwala Vijapurkar, Gary Meininger, Lawrence Blonde |
Journal | BMC health services research
(BMC Health Serv Res)
Vol. 16
Issue a
Pg. 356
(08 05 2016)
ISSN: 1472-6963 [Electronic] England |
PMID | 27495291
(Publication Type: Journal Article)
|
Chemical References |
- Blood Glucose
- Glucosides
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Sulfonylurea Compounds
- Thiophenes
- Canagliflozin
- glimepiride
- Metformin
|
Topics |
- Aged
- Blood Glucose
- Blood Pressure Determination
- Canagliflozin
(administration & dosage)
- Diabetes Mellitus, Type 2
(drug therapy)
- Double-Blind Method
- Female
- Glucosides
(therapeutic use)
- Glycated Hemoglobin
- Humans
- Hypoglycemia
- Hypoglycemic Agents
(administration & dosage)
- Male
- Metformin
(therapeutic use)
- Middle Aged
- Quality Indicators, Health Care
- Randomized Controlled Trials as Topic
- Sulfonylurea Compounds
(administration & dosage)
- Thiophenes
(therapeutic use)
- Treatment Outcome
|